CareDx is a global transplant diagnostics company with product offerings along the pre- and post-transplant continuum. The Company focuses on discovery, development, and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. CareDx's first commercialized post-transplant testing solution, the AlloMap heart transplant molecular test, or AlloMap, is a gene expression testing service that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate-to-severe acute cellular rejection.

The Company believes the use of AlloMap, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a heart transplant. In particular, AlloMap can improve patient care by helping healthcare providers avoid the use of unnecessary, invasive surveillance biopsies and determine the appropriate dosage levels of immunosuppressants. The Company is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure, its proprietary next-generation sequencing-based test to detect donor-derived cell-free DNA, or dd-cfDNA, after transplantation.

Show more
Type
Public
HQ
Brisbane, US
Founded
2000
Size (employees)
55 (est)
CareDx was founded in 2000 and is headquartered in Brisbane, US
Report incorrect company information

CareDx Office Locations

CareDx has an office in Brisbane
Brisbane, US (HQ)
3260 Bayshore Blvd
Show all (1)
Report incorrect company information

CareDx Financials and Metrics

CareDx Financials

CareDx's revenue was reported to be $48.32 m in FY, 2017
USD

Revenue (FY, 2017)

48.3 m

Net income (FY, 2017)

(55.6 m)

EBIT (FY, 2017)

(20.3 m)

Market capitalization (20-Apr-2018)

214.7 m

Cash (31-Dec-2017)

16.9 m

EV

231.8 m
CareDx's current market capitalization is $214.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

27.3 m28.1 m40.6 m48.3 m

Revenue growth, %

3%44%

Sales and marketing expense

6.5 m8.3 m11.2 m12.8 m

General and administrative expense

8.4 m12.2 m20.7 m18.9 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

7.1 m7.2 m6.6 m10.7 m12.5 m11.6 m12 m

Sales and marketing expense

2.5 m2.1 m1.7 m3.4 m3.5 m3.2 m3.3 m

General and administrative expense

2.3 m3.4 m5.7 m5.4 m5.2 m6.5 m4.1 m

R&D expense

2.5 m2.7 m3.2 m3.1 m2.9 m3.3 m3.1 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

36.4 m29.9 m17.3 m16.9 m

Accounts Receivable

2.7 m2.4 m2.8 m3 m

Inventories

686 k766 k5.5 m5.5 m

Current Assets

40.3 m34.4 m26.7 m26.8 m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

17.1 m22.3 m12.2 m9.1 m

Accounts Receivable

4.9 m4.6 m3.4 m3 m

Inventories

8.7 m7.4 m6 m6.3 m

Current Assets

32.5 m35.1 m23.1 m19.9 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

781 k(13.7 m)(39.8 m)

Depreciation and Amortization

512 k796 k2.9 m

Inventories

(168 k)(80 k)492 k

Accounts Payable

510 k489 k(620 k)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.2 m)(3.5 m)(9.8 m)(10.5 m)(3.8 m)(5.6 m)

Inventories

775 k731 k814 k595 k8.7 m7.4 m6 m

Accounts Payable

1.4 m1.2 m1.9 m2.5 m3.3 m3.5 m3.5 m
USDY, 2017

EV/EBIT

-11.4 x

Revenue/Employee

878.6 k

Financial Leverage

-14 x
Show all financial metrics
Report incorrect company information

CareDx News and Updates

Cell-Free DNA (cfDNA) Testing Market Expected to Generate Huge Profits by 2017 – 2025

The discovery of cfDNA has opened up to new potentials in the field of oncology, gynecology, transplantation and infectious diseases. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information